8-K: Akebia Drops Broad Vafseo Label for Non-Dialysis CKD

Akebia Therapeutics will not pursue a broad label for Vafseo in non-dialysis dependent chronic kidney disease patients after failing to align with the FDA on a clinical trial design.

Summary

• Akebia Therapeutics will not initiate the VALOR clinical trial for vadadustat (Vafseo) to treat anemia in late-stage chronic kidney disease (CKD) patients not on dialysis.
• This decision follows a Type C meeting with the U.S. Food and Drug Administration (FDA) where alignment on the trial design could not be reached.
• FDA feedback indicated that regulatory alignment for such a trial would require a significantly larger number of patients, leading to substantially more time and cost to complete.
• Akebia will therefore not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients.
• Vafseo is currently approved in the U.S. for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months, with prescriptions beginning in January 2025.
• The company remains focused on its goal to make Vafseo standard of care for patients on dialysis.
• Discussions with the FDA on potential clinical trial designs for smaller subgroups of CKD patients were encouraging.

Sentiment

Score: 3

Explanation: The news is negative as it closes off a significant potential market expansion for Vafseo due to regulatory hurdles. While the company is focusing on its approved indication and exploring smaller subgroups, the immediate impact is a reduction in future growth prospects for the drug.

Positives

• Vafseo is already approved in the U.S. for anemia due to CKD in adults on dialysis for at least three months, with prescriptions starting in January 2025.
• Akebia remains committed to making Vafseo the standard of care for patients on dialysis.
• Discussions with the FDA were encouraging regarding potential clinical trial designs for smaller subgroups of CKD patients not on dialysis.
• The decision to not pursue a broad NDD-CKD label is considered by management to be in the best interests of shareholders, as it avoids significant additional time and cost for a trial with uncertain regulatory alignment.

Negatives

• Akebia failed to reach alignment with the FDA on the design of the VALOR clinical trial for Vafseo in non-dialysis dependent CKD patients.
• The company will not initiate the VALOR trial, effectively abandoning the pursuit of a broad label for Vafseo in this significant patient population.
• FDA feedback indicated that a broad label trial would require a significantly larger number of patients, and meaningfully more time and cost, making it commercially unfeasible.
• This outcome is a disappointment for the company, which believes there is a significant unmet need for an oral option to treat anemia in CKD patients not on dialysis.

Risks

• VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE), death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access, especially if targeting a hemoglobin level greater than 11 g/dL.
• Hepatotoxicity, including hepatocellular injury, elevated serum ALT, AST, and bilirubin levels, was reported in less than 1% of patients, with one severe case.
• Worsening of hypertension was reported in 14% of VAFSEO patients, with serious worsening in 2.7%, and cases of hypertensive crisis.
• Seizures occurred in 1.6% of VAFSEO patients.
• Gastrointestinal (GI) erosion, including GI bleeding and the need for RBC transfusions, occurred in 6.4% of VAFSEO patients, with serious cases in 3.4%.
• In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa.
• VAFSEO has not been studied and is not recommended in patients with active malignancies.
• VAFSEO may cause fetal harm if used during pregnancy.
• Breastfeeding is not recommended until two days after the final dose of VAFSEO.
• VAFSEO is not recommended in patients with cirrhosis or active, acute liver disease.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties, including regulatory decisions, market acceptance, competition, manufacturing issues, and geopolitical factors.

Future Outlook

Akebia does not plan to initiate the VALOR clinical trial and therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients. The company remains focused on making Vafseo the standard of care for patients on dialysis and is encouraged by discussions with the FDA regarding potential clinical trial designs for smaller subgroups of CKD patients.

Management Comments

• "Because we remain steadfast in our belief of the significant unmet need for an oral option to treat anemia in CKD patients not on dialysis, we are disappointed in the outcome of the meeting." John P. Butler, Chief Executive Officer at Akebia.
• "We believe our decision not to pursue a broad NDD-CKD label, based on our discussion with the FDA, is in the best interests of our shareholders." John P. Butler, Chief Executive Officer at Akebia.
• "We were encouraged by the discussion with FDA on smaller subgroups of CKD patients where we may be able to align on a potential clinical trial design and path forward." John P. Butler, Chief Executive Officer at Akebia.
• "Importantly, everyone at Akebia will continue to work toward our goal to make Vafseo standard of care for patients on dialysis." John P. Butler, Chief Executive Officer at Akebia.

Industry Context

This announcement highlights the significant regulatory hurdles and high costs associated with expanding drug indications, particularly in complex patient populations like non-dialysis dependent CKD, where safety profiles are under intense scrutiny. The FDA's cautious stance reflects a broader trend of prioritizing patient safety, especially given the known risks associated with erythropoiesis-stimulating agents (ESAs) and similar mechanisms. Akebia's pivot to focus on the dialysis-dependent population, where Vafseo is already approved, is a common strategy for biopharmaceutical companies facing regulatory setbacks in broader indications.

Comparison to Industry Standards

• The FDA's requirement for a "significantly larger number of patients" for the VALOR trial aligns with the rigorous standards for drug approval in chronic conditions, especially given the safety concerns previously raised for HIF-PH inhibitors in non-dialysis CKD patients.
• Other HIF-PH inhibitors, such as roxadustat (FibroGen/AstraZeneca), have also faced significant regulatory challenges and delays in the U.S. for non-dialysis CKD due to safety concerns, ultimately receiving a narrower label or outright rejection for that population.
• The decision to discontinue pursuit of a broad label for Vafseo in NDD-CKD patients is comparable to the challenges faced by other companies developing similar drugs, where the benefit-risk profile in this population has been difficult to establish to the FDA's satisfaction.

Stakeholder Impact

• Shareholders: Negative impact due to the loss of a significant potential market expansion for Vafseo, potentially affecting future revenue and stock price. Management believes the decision is in their best interest by avoiding costly, uncertain trials.
• Patients (non-dialysis CKD): Loss of a potential oral treatment option for anemia, though Vafseo's safety profile in this group was a concern.
• Employees: Potential impact on R&D teams focused on the VALOR trial, though the company's overall mission remains.

Next Steps

• Continue to work toward making Vafseo standard of care for patients on dialysis.
• Explore potential clinical trial designs and paths forward for smaller subgroups of CKD patients not on dialysis, following encouraging discussions with the FDA.

Key Dates

Recommendation

The decision to abandon the broad non-dialysis CKD indication for Vafseo significantly limits the drug's total addressable market and future revenue potential. While Vafseo is approved for dialysis patients, the non-dialysis segment represented a much larger growth opportunity. The regulatory setback, requiring a "significantly larger number of patients" and "meaningfully more time and cost" for a broad label, indicates substantial hurdles that make the broad NDD-CKD market effectively inaccessible for Vafseo in the near term. This materially reduces the long-term growth prospects and valuation of the company, warranting a "sell" recommendation for investors seeking growth.

Keywords

Akebia Therapeutics, AKBA, Vafseo, vadadustat, FDA, VALOR, chronic kidney disease, CKD, non-dialysis, anemia, biopharmaceutical, regulatory update, drug development, pharmaceutical, kidney disease